The company has been focusing on the pharmaceutical industry, mainly producing 8 dosage forms such as powder injection, freeze-dried powder injection, small volume injection, large volume injection, tablet, capsule, granule and dry suspension. The company has 9 modern preparation production lines, 4 raw material drug production lines and 1 Chinese medicine extraction production line 1 line that meet the national GMP standards. The company has 238 national drug approval documents, and the drug categories mainly involve antibiotics, cardiovascular and cerebrovascular diseases, anti-tumor and antibiotics. Western medicine and Chinese medicine have developed simultaneously, with matching raw materials and preparations and complete new and special medicines. It can produce 10 dosage forms, and more than 200 kinds of raw materials, powder injections, freeze-dried powder injections, small-volume injections, large-volume injections, tablets, capsules, granules and dry suspensions. The products are sold to 3/kloc-0 provinces, municipalities and autonomous regions in China, and the freeze-dried area is 10.
By the end of 2004, all production lines of the company had passed GMP certification. At the end of June 2009 165438+ 10, the sales income was 9,065,438+million yuan, and the profits and taxes were 35.83 million yuan, including 20 million yuan.
201110/On October 7th, as the first enterprise in Shanxi Province to land on the Growth Enterprise Market, it was successfully listed on the Shenzhen Stock Exchange. The company's operation is in a period of rapid improvement, reaching a high level in one year, and the sales revenue in 20 10 reached1490,000, up by 44.5% year-on-year; In 20 10 year, the total industrial output value was 1.8 1 100 million, up 61.8% year-on-year; 20 10 realized profits and taxes of 64.26 million yuan, a year-on-year increase of 66.0%.